Table 4.
FEF in Infants at 3 Months of Age Incorporating α5 nAChR Genotype
| Vitamin C Mean (SD) (n = 112) | Placebo Mean (SD) (n = 105) | Adjusted Mean (95% CI) Difference without α5 Genotype (Vitamin C − Placebo)* | Adjusted P Value* | Adjusted Mean (95% CI) Difference with α5 Genotype (Vitamin C − Placebo)* | Adjusted P Value† | |
|---|---|---|---|---|---|---|
| FEF75, ml/s | 200.7 (70.0) | 188.7 (66.3) | 12.1 (−6.1 to 30.3) | 0.12 | 24.15 (−0.31 to 48.61) | 0.053 |
| FEF50, ml/s | 438.4 (100.2) | 406.4 (94.0) | 28.1 (2.3 to 54.0) | 0.016 | 47.00 (12.8 to 81.3) | 0.007 |
| FEF25–75, ml/s | 389.4 (96.3) | 363.8 (93.9) | 21.6 (−3.8 to 47.0) | 0.0493 | 40.00 (6.1 to 73.8) | 0.021 |
Definition of abbreviations: α5 nAChR = α5 nicotinic acetylcholine receptor; CI = confidence interval; FEF25–75 = forced expiratory flow between 25% and 75% of the expired volume; FEF50 = forced expiratory flow at 50% of the expired volume; FEF75 = forced expiratory flow at 75% of the expired volume.
*
P values and 95% CI adjusted for design factors of site; gestational age at randomization; and covariates of length, race, and sex.
†
P values and 95% CI adjusted for design factors of site; gestational age at randomization; and covariates of length, race, sex, and α5 nAChR genotype.